BSX BOSTON SCIENTIFIC CORP Insider Trading

Director Cheryl Pegus purchases initial 1,770 shares of BSX at $56.49 for $99,987.30

Director Cheryl Pegus acquired her first position in Boston Scientific, purchasing 1,770 shares at $56.49 on 2026-05-20 for a total value of $99,987.30. The purchase occurs near the lower end of the 52-week range ($52.52–$109.50), with the stock currently down 47.8% from its 52-week high and down 4.0% over 30 days and 23.4% over 90 days. Boston Scientific reported strong fundamentals with $5.2B quarterly revenue, $1.3B net income, and 19.9% annual revenue growth, though the stock trades at a P/E of 23.91. This initiation of a director position during a period of weakness merits monitoring to determine whether subsequent transactions establish a pattern of accumulation or represent a one-time addition to holdings.

Director Edward J Ludwig buys 3,580 shares of BSX at $56.68; stock -47.8% from 52-week high. Cluster pattern: 2 other insiders also bought within 14 days.

Edward J Ludwig, a Director, purchased 3,580 shares at $56.68 on 2026-05-20, increasing his holdings from 21,779 to 25,359 shares. This transaction coincides with a cluster buy signal: 2 other insiders have also purchased within the past 14 days. The stock is currently trading at $57.15, down 47.8% from its 52-week high of $109.50 and down 23.4% over the past 90 days. Ludwig's cross-ticker track record shows 2 prior buys with an average 90-day return of +12.0% and a 100.00% win rate, though his single prior sale at BSX on 2025-02-11 was well-timed with a 90-day return of -2.5%. The fundamental backdrop shows strong quarterly net income of $1,339,000,000.00 and annual revenue growth of +19.9%, though the P/E of 23.91 reflects market valuation pressures.

Director David C Habiger purchased 4,450 shares at Boston Scientific for $251,098.10 across two days, raising holdings +47.2%.

David C Habiger, a Director at Boston Scientific, executed two separate purchases totaling 4,450 shares for $251,098.10 on 2026-05-19 and 2026-05-20 at prices of $56.95 and $55.92 respectively, with a blended average of $56.43. This transaction increased his holdings from 9,428 shares to 13,878 shares, representing a +47.2% increase in his position. The current stock price of $57.15 is -47.8% from the 52-week high of $109.50 and down -23.4% over the past 90 days, placing this purchase within a period of significant price decline. Across his cross-ticker trade history, Habiger's prior six open-market buys show an average 90-day return of +6.2% with a 33.33% win rate, providing limited historical precedent for assessing whether this particular purchase will prove well-positioned.